Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs 10X Genomics Inc (TXG) Price & Performance

GraniteShares 2x Long COIN Daily ETFTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

GraniteShares 2x Long COIN Daily ETF vs 10X Genomics Inc — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $4.1, while 10X Genomics Inc trades at $56.71 (market cap $7.61B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals.

CONLTXG
Sector
Leveraged / InverseHealth
52-Week High
$48.70$58.57
52-Week Low
$3.93$11.34
Market Cap
$7.61B
Enterprise Value
$7.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GraniteShares 2x Long COIN Daily ETF

CONL (GraniteShares 2x Long COIN Daily ETF) trades at $4.065, down 0.61% on the day, with a bearish technical outlook as moving averages and key indicators signal selling pressure. The ETF has experienced significant volatility, losing 67% year-to-date according to 24/7 Wall Street (2026-06-06), reflecting the inherent risks of daily-reset leveraged strategies. Recent news highlights the challenges of timing leveraged ETF investments, with investors missing substantial returns due to poor trading timing.

The outlook remains challenging given the ETF's structure amplifies daily Coinbase volatility. While cryptocurrency trends may offer occasional upside, the daily reset mechanism creates compounding risks that have eroded value significantly. Investors should understand this is a tactical trading instrument, not a long-term investment vehicle, with high risk of capital erosion during volatile periods.

10X Genomics Inc

TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.

Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.

Returns comparison

Trailing returns across standard periods

About GraniteShares 2x Long COIN Daily ETF

CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.

Read more on CONL

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG